<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118624</url>
  </required_header>
  <id_info>
    <org_study_id>PDX-014</org_study_id>
    <secondary_id>2008-006425-14</secondary_id>
    <nct_id>NCT01118624</nct_id>
  </id_info>
  <brief_title>Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer</brief_title>
  <official_title>Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy (ability to provide a beneficial
      treatment of the disease) of pralatrexate for the treatment of female patients with advanced
      or metastatic breast cancer who have failed prior chemotherapy. Patients will receive vitamin
      B12 and folic acid supplementation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.</time_frame>
    <description>Tumor response evaluation was performed using RECIST 1.0 using CT/MRI. Proportion of patients achieving a CR or PR is considered in the overall response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.</time_frame>
    <description>One patient has a PR as response and duration of response was provided for that patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but at least every 4 weeks and no more than every 12 weeks (+/- 1 week) if treatment has ended. OS will be collected for up to 2 years from start of pralatrexate.</time_frame>
    <description>Number of days from first dose of pralatrexate to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Laboratory Abnormalities</measure>
    <time_frame>Recorded at all study visits: every 2 weeks while on treatment and at safety follow-up (35 +/- 5 days post-last dose) or early termination visit (at time of withdrawal).</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Tumors</condition>
  <condition>Neoplasms, Breast</condition>
  <condition>Cancer of the Breast</condition>
  <condition>Human Mammary Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pralatrexate Injection</intervention_name>
    <description>Intravenous (IV) push administration over 3-5 minutes.
Initial dose: 190 mg/m2
Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.
Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.</description>
    <other_name>FOLOTYN</other_name>
    <other_name>Pralatrexate</other_name>
    <other_name>PDX</other_name>
    <other_name>(RS)-10-propargyl-10-deazaaminopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B12</intervention_name>
    <description>1 mg intramuscular injection
Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate.</description>
    <other_name>Cyanocobalamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>1.0-1.25 mg orally
Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate.</description>
    <other_name>Vitamin B9</other_name>
    <other_name>Folate</other_name>
    <other_name>Folacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HER-2 negative advanced or metastatic breast cancer

          -  Disease has become worse after at least 1 prior chemotherapy regimen for advanced or
             metastatic disease

          -  Advanced or metastatic disease resistant to both a taxane and an
             anthracycline-containing chemotherapy regimen, or resistant to taxanes and for whom
             further anthracycline therapy is not indicated

          -  Patients with controlled brain metastases must have finished receiving radiation
             therapy and if on corticosteroids, be on a stable or tapering dose of â‰¤ 10 mg/day of
             prednisone or equivalent for at least 28 days prior to study entry

          -  Measurable disease

          -  Female 18 years of age or older

          -  Performance status less than or equal to 2

          -  Life expectancy of more than 3 months

          -  Blood, liver and kidney laboratory test results that meet protocol requirements

          -  Patients must have a negative serum pregnancy test within 14 days before enrollment
             and agree to use medically acceptable and effective birth control from enrollment
             until at least 30 days after the last dose of pralatrexate. Patients who are
             postmenopausal for at least 1 year (more than 12 months since last menses) or are
             surgically sterilized do not require this test.

          -  Willing to attend visits for repeat dosing and follow up

          -  Give written informed consent

        Exclusion Criteria:

          -  Patients with only bone metastasis

          -  Patients with a single metastatic site without histological proof that the lesion is
             metastatic breast cancer

          -  Patients with inflammatory breast cancer

          -  Treatment with systemic chemotherapy, hormone therapy, radiation therapy, or other
             investigational therapy within 3 weeks (6 weeks for nitrosoureas, mitomycin C) prior
             to enrollment, except for the following:

               -  Bisphosphonates, if ongoing

               -  Prior treatment with methotrexate

               -  Prior treatment with anti-angiogenics within 6 months prior to enrollment

          -  Have received more than 2 prior chemotherapy regimens (more than 3 if one of the
             treatments was neoadjuvant or adjuvant chemotherapy)

          -  Have previously received pralatrexate

          -  Have received more than the allowed maximum total dose of anthracycline

          -  Prior radiation therapy on more than 30% of bone marrow reserve or prior bone
             marrow/stem cell transplantation

          -  Congestive heart failure Class III/IV

          -  Uncontrolled hypertension (high blood pressure)

          -  Active infection or any serious medical condition, which would impair the ability of
             the patient to receive protocol treatment

          -  Females who are pregnant or breastfeeding

          -  Major surgery within 14 days of enrollment

          -  Another active cancer in addition to advanced or metastatic breast cancer, except well
             treated in situ cervical cancer and basal cell skin cancer

          -  Dementia or other altered mental status that would prevent the patient from
             understanding and giving informed consent or limit her ability to follow the study
             requirements

          -  Patients who are human immunodeficiency virus (HIV)-positive and have a CD4 count of
             less than 100 mm3 or detectable viral load within past 3 months and is receiving
             anti-retroviral therapy

          -  Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) who have a detectable
             viral load or immunological evidence of chronic active disease or receiving/requiring
             antiviral therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garry Weems, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Spectrum Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FakultnÃ­ nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiscan, s.r.o.</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FakultnÃ­ nemocnice KrÃ¡lovskÃ© Vinohrady - FNKV</name>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Lutte Contre le Cancer Val d'Aurelle (CRLC)</name>
      <address>
        <city>Montpellier</city>
        <state>Cedex 5</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre RÃ©gional de Lutte Contre le Cancer Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre</city>
        <state>les Nancy Cedex</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges FranÃ§ois Leclerc</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre LÃ©on BÃ©rard</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean-Godinot</name>
      <address>
        <city>Reims Cedex 09</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Medical and Health Science Center</name>
      <address>
        <city>Debrecen</city>
        <state>HajdÃº-Bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>H-1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Centre of Hungary</name>
      <address>
        <city>Budapest</city>
        <zip>H-1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <results_first_submitted>February 24, 2014</results_first_submitted>
  <results_first_submitted_qc>May 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2014</results_first_posted>
  <last_update_submitted>May 27, 2014</last_update_submitted>
  <last_update_submitted_qc>May 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Female</keyword>
  <keyword>Advanced</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Aminopterin</mesh_term>
    <mesh_term>10-deazaaminopterin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled between 05 Oct 2009 and 10 May 2011. Patients were enrolled in Hungary, France, and the Czech Republic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pralatrexate</title>
          <description>Study drug 190 mg/m^2 for 2 to 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients enrolled and treated with study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Pralatrexate</title>
          <description>Study drug 190 mg/m^2 for 2 to 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>Tumor response evaluation was performed using RECIST 1.0 using CT/MRI. Proportion of patients achieving a CR or PR is considered in the overall response.</description>
        <time_frame>Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pralatrexate</title>
            <description>Study drug 190 mg/m^2 for 2 to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>Tumor response evaluation was performed using RECIST 1.0 using CT/MRI. Proportion of patients achieving a CR or PR is considered in the overall response.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.1" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>One patient has a PR as response and duration of response was provided for that patient.</description>
        <time_frame>Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pralatrexate</title>
            <description>Study drug 190 mg/m^2 for 2 to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>One patient has a PR as response and duration of response was provided for that patient.</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Number of days from first dose of pralatrexate to death.</description>
        <time_frame>Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but at least every 4 weeks and no more than every 12 weeks (+/- 1 week) if treatment has ended. OS will be collected for up to 2 years from start of pralatrexate.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pralatrexate</title>
            <description>Study drug 190 mg/m^2 for 2 to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Number of days from first dose of pralatrexate to death.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="6.8" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events (AEs) and Laboratory Abnormalities</title>
        <time_frame>Recorded at all study visits: every 2 weeks while on treatment and at safety follow-up (35 +/- 5 days post-last dose) or early termination visit (at time of withdrawal).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pralatrexate</title>
            <description>Study drug 190 mg/m^2 for 2 to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs) and Laboratory Abnormalities</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All treated patients will be followed for safety through 35 (Â± 5) days after their last dose or until all treatment-related AEs have resolved or returned to baseline/Grade 1, whichever is longer</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pralatrexate</title>
          <description>Study drug 190 mg/m^2 for 2 to 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sufficient patients were enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pankaj Sharma, MD</name_or_title>
      <organization>Spectrum Pharmaceuticals</organization>
      <phone>949-743-9264</phone>
      <email>pankaj.sharma@sppirx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

